Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
CHAPEL HILL, N.C., Nov. 09, 2016 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in two upcoming investor conferences.
- Stifel 2016 Healthcare Conference, Lotte New York Palace Hotel, New York, November 15, 2016 at 9:30 a.m. EST
- Jefferies 2016 London Healthcare Conference, Waldorf Hilton, London, November 17, 2016 at 8:40 a.m. GMT
A live audio webcast and archive of the presentations will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin has been successfully evaluated in two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and applications for approval for both intravenous and oral capsule formulations have been accepted for review by the FDA and the EMA. Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Fusidic acid is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure infections (ABSSSI) and is also in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
Company Contact: John Bluth Cempra, Inc. +1 984 209 4534 [email protected] Investor Contact: Robert Uhl Westwicke Partners, LLC +1 858 356 5932 [email protected] Media Contact: Melyssa Weible Elixir Health PR +1 201 723 5805 [email protected]
